文献速递肝病消化道肿瘤与早癌

恩替卡韦与替诺福韦治疗慢性乙肝患者肝癌风险无差异

No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
PubMed 文献 · Gut · 2020-03-30

该回顾性队列研究纳入美国退伍军人中接受恩替卡韦或替诺福韦治疗的慢性乙肝患者,平均随访5.4年,发现两组肝癌风险及死亡或肝移植风险均无显著差异,支持两者均为一线治疗选择。

要点

  • 恩替卡韦与替诺福韦治疗慢性乙肝患者肝癌风险无差异(aHR 1.00)。
  • 两组死亡或肝移植风险亦无差异(aHR 1.16)。
  • 结果支持指南推荐两者均为慢性乙肝一线治疗药物。

核心结论

  • 恩替卡韦与替诺福韦治疗慢性乙肝患者的肝癌风险无差异,死亡或肝移植风险亦无差异。

研究设计与样本

  • 回顾性队列研究,纳入美国退伍军人中慢性乙肝患者,恩替卡韦组2193例,替诺福韦组1094例,平均随访5.4年。

主要发现

  • 恩替卡韦组与替诺福韦组肝癌风险无差异(aHR 1.00,95%CI 0.76-1.32)。
  • 死亡或肝移植风险无差异(aHR 1.16,95%CI 0.98-1.39)。
  • 倾向评分调整、竞争风险分析及多重敏感性分析结果一致。

临床怎么用

  • 临床可依据指南将恩替卡韦或替诺福韦均作为慢性乙肝一线治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are first-line agents for the treatment of chronic hepatitis B (CHB). Recent studies have challenged the assumption that these agents are equally effective at preventing hepatocellular carcinoma (HCC). We aimed to determine whether the risk of HCC and mortality differ in patients with CHB treated with ETV and TDF. DESIGN: We performed a retrospective cohort study of Veterans Affairs patients with CHB in the USA who initiated treatment with ETV or TDF between the dates of Food and Drug Administration approval of these medications and 1 January 2017. Multivariable Cox proportional hazards regression was used to determine the association between antiviral therapy and HCC risk as well as the risk of death or liver transplantation. Propensity score adjustment and competing risks analysis were performed. RESULTS: We identified 2193 ETV-treated and 1094 TDF-treated patients who were followed for a mean of 5.4 years. We found no difference in the risk of HCC in ETV-treated versus TDF-treated patients (adjusted HR (aHR) 1.00, 95% CI 0.76 to 1.32). Results were similar in propensity score adjusted and competing risks analysis, and in multiple sensitivity analyses. We also found no difference in the risk of death or liver transplantation (aHR 1.16, 95% CI 0.98 to 1.39). CONCLUSIONS: We found no difference in the risk of HCC between patients with CHB treated with ETV versus TDF. Our results support current guideline recommendations that both agents are appropriate first-line options for the treatment of CHB.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Su F, Berry K, Ioannou GN, et al. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut. 2020. PMID: 32229544. doi:10.1136/gutjnl-2019-319867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。